Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma

NCT03893695 is registered in ClinicalTrials.gov with Suzhou Kintor Pharmaceutical Inc, as lead sponsor.

NCT NCT03893695
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03893695 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma
Lead sponsor
Suzhou Kintor Pharmaceutical Inc,
Phase
Phase 1/2
Overall status
Completed
Start date
May 25, 2019
Completion date
September 27, 2022
Enrollment
20 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

combinations of drugs; dependence, hcc, metastatic hepatocellular carcinoma